Xtalks
246 episodes listed below
PRESS PLAY
This Life Science focused podcast brings together Xtalks editorial staff to share insights into the latest B2B industry news. Xtalks connects professionals in the life science, medical device, and food industries with useful content like webinars, job opening, articles and virtual meetings.
Based on 4 episodes we listened to · September 2026
Aisha Rashid connects biomedical mechanisms with the partnerships, financing, development choices, and reimbursement systems that shape which medicines reach patients.
Xtalks Life Science Podcast follows scientific ideas into the institutions, companies, partnerships, and payment systems that determine whether they reach patients.
Aisha Rashid takes the gene therapy pitch to the reimbursement system; you hear the awkward math.
Press play if you want
Short reviews from the PlayNext desk, based on the episodes we processed.
A practical look at how donor-derived bone marrow could fit into allogeneic transplant workflows.
Bone marrow transplantation comes through here as a question of logistics as much as biology. In conversation with Kevin Caldwell, CEO, co-founder, and president of Ossium Health, the episode traces how organ donor-derived marrow might be selected for a patient, shipped before…
A company-led look at cannabinoid and psychedelic therapies, grounded in clinical development detail and phase two sleep apnea data.
Joel Latham frames cannabinoid pharmaceuticals and psychedelic therapies through the day-to-day realities of clinical development, with Inconnex Healthcare's pipeline spanning obstructive sleep apnea, rheumatoid arthritis, and generalized anxiety disorder.
A measured look at refining established science and older drugs into combination strategies against cancer resistance.
General Oncology's strategy begins with a grounded question: how can older drugs and established science be reshaped into treatments that may help cure or control disease?
A clear, measured review of how CAR-NK cells may move from platform promise toward clinical use.
Cell therapy is treated here less as a single breakthrough than as a question of biological fit and clinical timing. Dr. Ian Nisbet, Chief Operating Officer and co-founder of Cartherix, explains the company's work to create an effectively unlimited supply of CAR-NK cells, then…
A clear, grounded look at why fibrosis makes MASH a serious liver-disease challenge.
MASH comes across as a serious liver-disease challenge with consequences that reach well beyond liver fat alone. Patients may progress toward cirrhosis and transplant, while cardiovascular morbidity and mortality add another layer of risk for those with high liver fat, fibrosis,…
Mushroom culture from soil to society.
Clear neuroscience for curious minds.
Plant papers, jokes, and useful uncertainty.
Weed science, from genomes to paddocks.
Biomedical careers, described from the inside.
Human stakes behind biomedical progress.
Jason Matuszewski, CEO of BioStem Technologies, explains how iterating on placental tissue processing cut time from about 10 hours to 5-6 hours and produced the BioRetain method, which he compares to "organic, natural bread." He reports preliminary diabetic foot ulcer data showing "two times greater effect" than standard of care, with a venous leg ulcer study still enrolling.
Elizabeth Jeffords, CEO of Iolyx Therapeutics, explains why her company targets Th1 and Th17 inflammation in eye disease rather than building "another anti-VEGF company." She describes autoimmune dry eye patients as more severe and often excluded from trials, noting that a single Facebook ad recruited perimenopausal women for Iolyx's phase two study.
Dr.
Dr.
Dr. Menzies-Gow compares reliever-only asthma treatment to taking a painkiller for a broken arm without fixing the break.
Patients with this bile duct disease have no treatment and a very high risk of cholangiocarcinoma.
UCB listened to more than 246,000 social posts instead of surveying women, because a survey presumes you already know their questions.
Dr.
Dr.
Dr.
Dr.
Dompe Chief Development Officer Dr.
Vanderklish says biotech teams should "try early on to kill your own technology" so it fails before patients are involved.
Roughly 80% of rare diseases are genetic, yet less than 5% have an approved treatment today.
The FDA qualified DEXA bone mineral density in December 2025 as the first surrogate endpoint for fractures in anti-osteoporosis drug trials in postmenopausal women, and FNIH's Dr.
Aisha Rashid interviews Kevin Caldwell, CEO, co-founder, and president of Ossium Health, about using cryopreserved bone marrow from deceased organ donors for allogeneic transplantation.
Aisha Rashid interviews Joel Latham, CEO, President, and Director of Inconnex Healthcare, about cannabinoid pharmaceuticals and psychedelic therapies for obstructive sleep apnea, generalized anxiety disorder, and rheumatoid arthritis.
Jeff Glazier, CEO and founding member of General Oncology, describes moving from Harvard Law School and startup work into cancer drug development after his aunt Sharon’s pancreatic cancer treatment.
Xtalks Life Science Podcast host Aisha Rashid interviews Cartherics COO and co-founder Dr.
Rohan Palekar, CEO of 89Bio, explains how MASH progresses from liver fat and inflammation to fibrosis and cirrhosis, with U.S.
Interview with Dr.
Aisha Rashid interviews Roger Cohn, founder of Courage Therapeutics and University of Michigan professor, about MC3R and MC4R pathways regulating hunger, energy storage, and body weight.
Aisha Rashid interviews Artax Biopharma CEO Dr.
Dr.
Xtalks Life Science Podcast host Aisha Rashid interviews Neurizon Therapeutics CEO Dr.
Dr.
Dr.
Gene Mack, CEO and President of Gain Therapeutics, explains the company’s effort to develop disease-modifying therapies for Parkinson’s disease and other neurodegenerative conditions.
Jasper Therapeutics CMO Dr.
Ayesha Rishi interviews CancerVax Principal Scientist Adam Grant about a Universal Cancer Treatment Platform that uses marker-one targeting and smart mRNA to make cancer cells resemble viruses such as measles.
An interview with the President of Nestle Health Science about pharmaceutical therapies and gut health treatments.
Interview with Jerry McLaughlin, CEO of Life Biosciences, discussing their gene therapy for optic neuropathies and cellular rejuvenation to reverse aging diseases.
An interview with Dr.
Interview with Marcy English about the FDA-approved drug Fezolinitin for menopause symptoms.